Table 2

Comparison of demographic, clinical and laboratory features of SSc patients with high and normal concentration of sCD163 and high and normal sCD163/sTWEAK ratios.

Characteristica

sCD163

sCD163/sTWEAK


High* (n = 13)

Normal (n = 76)

P-value

High* (n = 29)

Normal (n = 60)

P-value


Age, years

56.08 ± 16.11

57.42 ± 11.67

NS

59.38 ± 12.86

56.18 ± 12.01

NS

Disease duration, years

8.23 ± 6.91

11.66 ± 9.29

NS

11.53 ± 7.81

10.23 ± 9.55

NS

Duration of RP (data available for 54 patients), years

11.46 ± 8.04

9.11 ± 8.58

NS

10.36 ± 7.55

9.32 ± 8.82

NS

DSSc, n/total

5/13 (38.46%)

15/76 (19.74%)

NS

10/29 (34.48%)

10/60 (16.67%)

0.055

mRSS (data available for 72 patients)

10.92 ± 9.78

7.95 ± 6.58

NS

12.30 ± 9.68

6.63 ± 4.85

0.0085

ILD, n/total

9/13 (69.23%)

46/76 (60.53%)

NS

17/29 (58.6%)

38/60 (63.33%)

NS

PH, n/total (data available for 81 patients)

2/13 (15.39%)

2/68 (2.94%)

NS

2/29 (6.90%)

2/52 (3.85%)

NS

FVC (data available for 75 patients), % of predicted

86.33 ± 19.89

94.56 ± 21.61

NS

95.42 ± 23.40

92.37 ± 20.26

NS

DLCO (data available for 53 patients), % of predicted

74.38 ± 22.94

80.10 ± 30.32

NS

73.16 ± 24.73

82.19 ± 30.97

NS

PASP (data available for 56 patients), mmHg

32.86 ± 12.03

29.23 ± 10.99

NS

29.00 ± 9.25

30.13 ± 12.23

NS

Digital ulcers, n/total

1/13 (7.69%)

37/76 (46.68%)

0.005

5/29 (17%)

33/60 (55%)

0.0006

Anti-topo I, n/total

4/13 (30.77%)

31/76 (40.79%)

NS

10/29 (35%)

25/60 (41.67%)

NS

ACA, n/total

3/13 (23.08%)

30/76 (39.47%)

NS

9/29 45%)

24/60 (40%)

NS

ESR (data available for 51 patients), mm/h

28.18 ± 21.05

21.78 ± 19.27

NS

19.64 ± 11.47

24.49 ± 21.93

NS

Arterial hypertension, n/total

2/13 (15.39%)

6/76 (7.90%)

NS

3/29 (10.35%)

5/60 (8.33%)

NS

CCBs, n/total

Pentoxyphylline, n/total

ACEIs, n/total

Sildenafil, n/total

NSAIDs, n/total

3/13 (23.08%)

5/13 (38.46%)

4/13 (30.77%)

1/13 (7.69%)

3/13 (23.08%)

25/76 (32.90%)

29/76 (38.16%)

8/76 (10.53%)

3/76 (3.95%)

10/76 (13.16%)

NS

NS

NS

NS

NS

8/29 (27.58%)

7/29 (24.14%)

4/29 (13.79%)

1/29 (3.45%)

4/29 (13.79%)

19/60 (31.67%)

26/60 (43.33%)

8/60 (13.33%)

3/60 (5.00%)

9/60 (15.00%)

NS

NS

NS

NS

NS


Because high concentrations of sTWEAK were found in two SSc patients only, no reliable statistical comparisons between SSc patients with high and those with normal sTWEAK concentration could be performed. Values are given as mean ± SD unless stated otherwise. aData available for 89 patients unless stated otherwise. *The high concentration of sCD163 and high sCD163/sTWEAK ratio was defined as a value greater than the mean + 2 SD of the value in healthy controls. sTWEAK, soluble tumour necrosis factor-like weak inducer of apoptosis; NS, not significant (P >0.05); ACA, anticentromere antibodies; ACEIs, angiotensin-converting enzyme inhibitors; ANA, antinuclear antibodies; CCBs, calcium channel blockers; DLCO, diffusing capacity of the lungs for carbon monoxide; dSSc, diffuse systemic sclerosis; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; HRCT, high resolution computed tomography; ILD, scleroderma interstitial lung disease; mRSS, modified Rodnan skin score; NSAIDs, non-steroidal anti-inflammatory drugs; PASP, pulmonary artery systolic pressure; PH, pulmonary hypertension; RP, Reynaud's phenomenon.

Kowal-Bielecka et al. Arthritis Research & Therapy 2013 15:R69   doi:10.1186/ar4246

Open Data